share_log

8-K/A: Current report (Amendment)

8-K/A: Current report (Amendment)

8-K/A:重大事件(修正)
美股SEC公告 ·  06/27 16:39
Moomoo AI 已提取核心信息
Illumina, Inc., a leading biotechnology company, has successfully completed the spin-off of its subsidiary GRAIL, Inc. on June 24, 2024. The separation was executed as a tax-free distribution of 26.5 million shares of GRAIL common stock to Illumina shareholders, with Illumina retaining a 14.5% ownership stake in GRAIL. The spin-off resulted in GRAIL becoming an independent public company, trading under the symbol 'GRAL' on the NASDAQ Global Select Market as of June 25, 2024. To facilitate the spin-off, Illumina provided GRAIL with $974 million in Disposal Funding, less GRAIL's cash on hand at the time of the spin-off. To fund this, Illumina entered into a credit agreement for a $750 million term loan with a variable interest rate, which was fully drawn...Show More
Illumina, Inc., a leading biotechnology company, has successfully completed the spin-off of its subsidiary GRAIL, Inc. on June 24, 2024. The separation was executed as a tax-free distribution of 26.5 million shares of GRAIL common stock to Illumina shareholders, with Illumina retaining a 14.5% ownership stake in GRAIL. The spin-off resulted in GRAIL becoming an independent public company, trading under the symbol 'GRAL' on the NASDAQ Global Select Market as of June 25, 2024. To facilitate the spin-off, Illumina provided GRAIL with $974 million in Disposal Funding, less GRAIL's cash on hand at the time of the spin-off. To fund this, Illumina entered into a credit agreement for a $750 million term loan with a variable interest rate, which was fully drawn on June 20, 2024. The pro forma financial statements reflect the financial position and results of operations as if the spin-off had occurred at the beginning of the periods presented. The pro forma balance sheet shows a reduction in assets and liabilities due to the spin-off, and the pro forma statements of operations reflect the removal of GRAIL's financial results from Illumina's post-spin-off.
领先的生物技术公司Illumina成功完成了其子公司GRAIL的剥离,时间为2024年6月24日。剥离以免税方式进行,将GRAIL普通股的2650万股送给了Illumina股东,而Illumina保留了GRAIL14.5%的股权。剥离导致GRAIL成为一个独立的上市公司,从2024年6月25日起在纳斯达克全球精选市场上交易,代码为“GRAL”。为了促进公司剥离,Illumina为GRAIL提供了97400万美元的处置资金(减去剥离时GRAIL手头的现金)。为此,Illumina与银行签署了一个75000万美元的(利率可变的)借款期限协议,该协议于2024年6月20日全额贷款。经过预测后的财务报表反映了展开当时已发生的剥离的财务状况和营运结果。预测后的资产负债表显示出由于剥离的原因而导致的资产和负债减少,而预测后的利润表反映了GRAIL的财务结果从Illumina的发帖中删除的情况。
领先的生物技术公司Illumina成功完成了其子公司GRAIL的剥离,时间为2024年6月24日。剥离以免税方式进行,将GRAIL普通股的2650万股送给了Illumina股东,而Illumina保留了GRAIL14.5%的股权。剥离导致GRAIL成为一个独立的上市公司,从2024年6月25日起在纳斯达克全球精选市场上交易,代码为“GRAL”。为了促进公司剥离,Illumina为GRAIL提供了97400万美元的处置资金(减去剥离时GRAIL手头的现金)。为此,Illumina与银行签署了一个75000万美元的(利率可变的)借款期限协议,该协议于2024年6月20日全额贷款。经过预测后的财务报表反映了展开当时已发生的剥离的财务状况和营运结果。预测后的资产负债表显示出由于剥离的原因而导致的资产和负债减少,而预测后的利润表反映了GRAIL的财务结果从Illumina的发帖中删除的情况。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息